Becker’s Healthcare Podcast

Episode: Rob Andrews on Employer Led Health Care Reform and the Future of Health Plans
Date: February 21, 2026
Host: Scott King
Guest: Rob Andrews, CEO of Health Transformation Alliance

Episode Overview

This episode features a conversation with Rob Andrews, CEO of the Health Transformation Alliance (HTA) and former US Congressman, focusing on the evolution of employer-led healthcare reform and the future of health plans. Rob shares his perspectives on how the relationships between employers, payers, and providers are shifting, the growing importance of outcome-based competition, emerging technologies in personalized medicine, and the pressing challenges facing employer-sponsored health plans—particularly around drug pricing and transparency.

Key Discussion Points and Insights

Rob Andrews’ Background and Perspective

• Rob’s career: Served for 25 years in the US House of Representatives (helped enact the Affordable Care Act), then practiced law and now leads HTA, a coalition of 80+ major employers seeking higher-value healthcare.
  • Rob’s experience spans being a legislator, lawyer, patient, and now industry leader.
  • Quote (01:06): "Our job really is to look for the highest value care, not the cheapest care, but the highest value care that produce the best results."

The Changing Employer-Provider Relationship

• Providers and employers facing parallel challenges:
  • Providers under extreme financial pressure, shrinking reimbursements, and workforce shortages.
  • Employers experiencing ballooning healthcare costs (9%+ annual increases), but not commensurate improvements in quality.
• New Cooperation:
  • Shift towards greater collaboration, with less dominance by insurance carriers or pharmacy benefit managers (PBMs).
  • Quote (02:32): "More and more employers and providers are looking for a way to solve [critical problems] together. Not to the exclusion necessarily of carriers or PBMs, but probably with those groups playing a less important role and providers and employers playing a more prominent and primary role."
  • Quote (03:52): "If you've got an environment where employers are paying 9% more, but providers have seen their margins cut by two thirds or disappearing, the money is going in some cases to middlemen... Is it the right share? And I think the answer is usually no."

Where Is the Biggest Gap? Carrier Competition and Quality

• Lack of true competition:
  • Carriers compete on price, not outcomes. Rob argues for competition to pivot towards results and health outcomes, not just discounts.
  • Quote (05:54): "Carriers should be competing on the basis of outcome, who helps to make people healthier, not on the basis of rates or discounts."

The Next Big Disruptor: Personalized Medication with AI

• Pharmacogenomics and AI:
  • Technology will soon make it possible to match the right medication to the right patient, leveraging genetics and comorbidities.
  • Current formularies are economically, not clinically, driven; personalization will drive better outcomes and contain costs, especially as drug prices soar.
  • Quote (06:50): "I think you're going to see the market move toward more personalized formularies… That, I think, will lead to much better outcomes. Fewer cardiac incidents, fewer gastro incidents and so forth."
• Why it’s coming soon:
  • Drug cost escalation is a major pain point.
  • AI can synthesize data on drug interactions, genetics, and co-conditions.
  • Costs of these technologies are dropping rapidly.
  • Quote (08:19): "Pharmacogenomics which was fairly exotic and expensive a decade ago, will become a lot more common and less expensive. It'll be used by more providers and it'll lead to better outcomes."

Regulatory and Industry Practice Changes: Transparency is Key

• Problem: Gag Clauses and Lack of Price Transparency
  • Gag clauses prevent true transparency in pricing between providers, networks, and PBMs, leading to confusion and inefficiency in the market.
  • Rob calls for legislative action to ensure all parties know “the real cost.”
  • Quote (09:21): "You can't have an effective market unless people know what the real cost is that they're being asked to bear and what the benefit of it is. So… let pricing be known, I think would disrupt the industry in a positive way."

Most Pressing Issue for Employer Plans: Drug Pricing for GLP-1s

• GLP-1 drugs (for diabetes/weight loss) as immediate margin threat
  • Rapidly rising use and cost, but pricing inconsistencies between direct-to-consumer and employer plans is unsustainable.
  • Employers are considering workarounds—direct reimbursement to consumers, or pushing PBMs/manufacturers for price normalization.
  • Quote (10:40): "If a drug is being sold for $190 a month to someone who puts their credit card down, but it's $500 a month net of rebates for employer plan. Employers are going to do something to change that."

Notable Quotes & Memorable Moments

• On the employer-provider alliance:
  "Never let a good crisis go to waste." (02:32, paraphrased Rahm Emanuel, with attribution by Rob Andrews)

• On changing the game for PBMs and carriers:
  "The person...doing the actual healing work, that more of the money goes to the provider and less of it goes to the people in the middle..." (04:19)

• On the promise of AI in personalized medicine:
  "AI to understand the relationship among drugs, drugs with certain comorbidities, the genetic characteristics of the patient... will become a lot more common and less expensive." (08:19)

Timestamps for Important Segments

• 00:50–01:45: Rob Andrews introduces his background and the mission of HTA.
• 02:15–03:55: New dynamics between providers and employers; middlemen under scrutiny.
• 05:54–06:42: Call for outcome-based competition among carriers.
• 06:50–08:19: Personalized medicine, AI, and pharmacogenomics as the next major disruptors.
• 09:13–10:22: Transparency and gag clauses as a root industry challenge.
• 10:40–11:57: GLP-1 pricing exposing unsustainable gaps for employer-sponsored health plans.

Conclusion

Rob Andrews brings a rare and comprehensive perspective spanning legislation, employer coalitions, and patient advocacy. He sees a future where employers and providers forge stronger, more direct alliances, with technology and transparency as key levers for change. The rising costs—especially of breakthrough drugs—and a lack of price clarity threaten sustainability, but also present an inflection point for genuine reform in the health plan landscape.